Crinetics Pharmaceuticals (NASDAQ: CRNX) has announced its participation in the upcoming Jefferies Global Healthcare Conference 2025, scheduled for June 3-5, 2025 in New York. The company's management will deliver a presentation on Thursday, June 5, 2025, at 12:50 p.m. Eastern Time. Investors can access the live and archived webcast through the Events & Presentations page in the Investors section of Crinetics' website. One-on-one meetings with management can be arranged through conference representatives.
Crinetics Pharmaceuticals (NASDAQ: CRNX) ha annunciato la sua partecipazione al prossimo Jefferies Global Healthcare Conference 2025, che si terrà dal 3 al 5 giugno 2025 a New York. Il management dell'azienda terrà una presentazione giovedì 5 giugno 2025 alle 12:50 ora della costa orientale. Gli investitori potranno seguire la diretta e accedere alla registrazione tramite la pagina Eventi e Presentazioni nella sezione Investitori del sito web di Crinetics. È possibile organizzare incontri individuali con il management tramite i rappresentanti della conferenza.
Crinetics Pharmaceuticals (NASDAQ: CRNX) ha anunciado su participación en la próxima Jefferies Global Healthcare Conference 2025, que se celebrará del 3 al 5 de junio de 2025 en Nueva York. La dirección de la empresa realizará una presentación el jueves 5 de junio de 2025 a las 12:50 p.m., hora del Este. Los inversores podrán acceder a la transmisión en vivo y a la grabación a través de la página de Eventos y Presentaciones en la sección de Inversores del sitio web de Crinetics. Las reuniones individuales con la dirección se pueden coordinar a través de los representantes de la conferencia.
Crinetics Pharmaceuticals (NASDAQ: CRNX)는 2025년 6월 3일부터 5일까지 뉴욕에서 개최되는 Jefferies Global Healthcare Conference 2025에 참가한다고 발표했습니다. 회사 경영진은 2025년 6월 5일 목요일 동부 표준시 기준 오후 12시 50분에 발표를 진행할 예정입니다. 투자자들은 Crinetics 웹사이트 투자자 섹션의 이벤트 및 프레젠테이션 페이지를 통해 생중계 및 녹화 영상을 시청할 수 있습니다. 경영진과의 1:1 미팅은 컨퍼런스 관계자를 통해 예약할 수 있습니다.
Crinetics Pharmaceuticals (NASDAQ : CRNX) a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference 2025, qui se tiendra du 3 au 5 juin 2025 à New York. La direction de l'entreprise présentera le jeudi 5 juin 2025 à 12h50, heure de l'Est. Les investisseurs pourront accéder à la diffusion en direct ainsi qu'à l'archive via la page Événements et Présentations dans la section Investisseurs du site web de Crinetics. Des réunions individuelles avec la direction peuvent être organisées via les représentants de la conférence.
Crinetics Pharmaceuticals (NASDAQ: CRNX) hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference 2025 angekündigt, die vom 3. bis 5. Juni 2025 in New York stattfindet. Die Geschäftsleitung des Unternehmens wird am Donnerstag, den 5. Juni 2025, um 12:50 Uhr Eastern Time eine Präsentation halten. Investoren können den Live-Stream sowie die Aufzeichnung über die Seite "Events & Presentations" im Investor-Bereich der Crinetics-Website abrufen. Einzelgespräche mit der Geschäftsleitung können über die Vertreter der Konferenz arrangiert werden.
Positive
None.
Negative
None.
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY.
Jefferies Global Healthcare Conference 2025 Company presentation: Thursday, June 5, 2025 at 12:50 p.m. Eastern Time Webcast link:HERE
The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events.
If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.
ABOUT CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors: Gayathri Diwakar Head of Investor Relations gdiwakar@crinetics.com (858) 345-6340
Media: Natalie Badillo Head of Corporate Communications nbadillo@crinetics.com (858) 345-6075
FAQ
When is Crinetics Pharmaceuticals (CRNX) presenting at the Jefferies Global Healthcare Conference 2025?
Crinetics Pharmaceuticals will present on Thursday, June 5, 2025, at 12:50 p.m. Eastern Time.
Where can I watch Crinetics Pharmaceuticals' (CRNX) presentation at the Jefferies Conference?
The presentation can be accessed via webcast through the Events & Presentations page in the Investors section of Crinetics' website at www.crinetics.com/events.
How can investors arrange meetings with Crinetics Pharmaceuticals' (CRNX) management at the Jefferies Conference?
Investors can arrange 1x1 meetings with management by contacting their conference representative.
Where is the Jefferies Global Healthcare Conference 2025 being held?
The conference is taking place in New York, NY from June 3-5, 2025.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
